The University of Chicago Header Logo

Connection

Ravi Salgia to Animals

This is a "connection" page, showing publications Ravi Salgia has written about Animals.
Connection Strength

1.983
  1. RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. Biochim Biophys Acta Rev Cancer. 2022 09; 1877(5):188803.
    View in: PubMed
    Score: 0.056
  2. Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Lett. 2021 10 10; 518:10-22.
    View in: PubMed
    Score: 0.051
  3. RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. Carcinogenesis. 2021 05 28; 42(5):742-752.
    View in: PubMed
    Score: 0.051
  4. Group Behavior and Emergence of Cancer Drug Resistance. Trends Cancer. 2021 04; 7(4):323-334.
    View in: PubMed
    Score: 0.050
  5. Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512.
    View in: PubMed
    Score: 0.050
  6. MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
    View in: PubMed
    Score: 0.048
  7. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
    View in: PubMed
    Score: 0.047
  8. The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends Mol Med. 2020 01; 26(1):119-134.
    View in: PubMed
    Score: 0.045
  9. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.041
  10. The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer. 2018 02; 4(2):110-118.
    View in: PubMed
    Score: 0.041
  11. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
    View in: PubMed
    Score: 0.040
  12. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.039
  13. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
    View in: PubMed
    Score: 0.037
  14. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biol Ther. 2016; 17(1):91-103.
    View in: PubMed
    Score: 0.035
  15. Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine. 2015 Nov; 11(8):1971-4.
    View in: PubMed
    Score: 0.034
  16. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
    View in: PubMed
    Score: 0.033
  17. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
    View in: PubMed
    Score: 0.032
  18. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
    View in: PubMed
    Score: 0.031
  19. Mitochondrial dynamics: biology and therapy in lung cancer. Expert Opin Investig Drugs. 2014 May; 23(5):675-92.
    View in: PubMed
    Score: 0.031
  20. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.031
  21. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.030
  22. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
    View in: PubMed
    Score: 0.030
  23. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
    View in: PubMed
    Score: 0.029
  24. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.028
  25. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011 Dec; 11(12):1655-62.
    View in: PubMed
    Score: 0.026
  26. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010 Jan-Mar; 4(1):146-52.
    View in: PubMed
    Score: 0.023
  27. MET pathway as a therapeutic target. J Thorac Oncol. 2009 Apr; 4(4):444-7.
    View in: PubMed
    Score: 0.022
  28. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S52-8.
    View in: PubMed
    Score: 0.022
  29. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.022
  30. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 2008 Jun; 7(6):856-63.
    View in: PubMed
    Score: 0.020
  31. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
    View in: PubMed
    Score: 0.020
  32. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
    View in: PubMed
    Score: 0.019
  33. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007 Mar; 9(2):102-8.
    View in: PubMed
    Score: 0.019
  34. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
    View in: PubMed
    Score: 0.019
  35. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9.
    View in: PubMed
    Score: 0.017
  36. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26.
    View in: PubMed
    Score: 0.016
  37. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004 Aug 06; 4:589-604.
    View in: PubMed
    Score: 0.016
  38. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res. 2004; 119:121-38.
    View in: PubMed
    Score: 0.015
  39. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
    View in: PubMed
    Score: 0.015
  40. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003 Sep 01; 63(17):5462-9.
    View in: PubMed
    Score: 0.015
  41. Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models. Semin Radiat Oncol. 2023 07; 33(3):279-286.
    View in: PubMed
    Score: 0.015
  42. The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action. Biochim Biophys Acta Rev Cancer. 2023 07; 1878(4):188929.
    View in: PubMed
    Score: 0.015
  43. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head Neck. 2023 05; 45(5):1255-1271.
    View in: PubMed
    Score: 0.014
  44. 2-methoxyestradiol alters cell motility, migration, and adhesion. Blood. 2003 Jul 01; 102(1):289-96.
    View in: PubMed
    Score: 0.014
  45. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
    View in: PubMed
    Score: 0.014
  46. Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71.
    View in: PubMed
    Score: 0.014
  47. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1.
    View in: PubMed
    Score: 0.014
  48. Molecular alterations in lung cancer. Impact on prognosis. Methods Mol Med. 2003; 75:29-38.
    View in: PubMed
    Score: 0.014
  49. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
    View in: PubMed
    Score: 0.014
  50. Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases. Methods Mol Med. 2003; 85:87-105.
    View in: PubMed
    Score: 0.014
  51. Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning system. Int J Biol Macromol. 2022 Oct 31; 219:366-373.
    View in: PubMed
    Score: 0.014
  52. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002 Feb; 13(1):41-59.
    View in: PubMed
    Score: 0.013
  53. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
    View in: PubMed
    Score: 0.013
  54. ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. Mol Oncol. 2021 07; 15(7):1866-1881.
    View in: PubMed
    Score: 0.013
  55. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
    View in: PubMed
    Score: 0.013
  56. Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Mol Carcinog. 2021 03; 60(3):213-223.
    View in: PubMed
    Score: 0.012
  57. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem. 2020 09 18; 295(38):13393-13406.
    View in: PubMed
    Score: 0.012
  58. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
    View in: PubMed
    Score: 0.012
  59. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
    View in: PubMed
    Score: 0.012
  60. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog. 2000; 11(1):63-76.
    View in: PubMed
    Score: 0.012
  61. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
    View in: PubMed
    Score: 0.012
  62. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
    View in: PubMed
    Score: 0.012
  63. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett. 2019 10 01; 461:123-131.
    View in: PubMed
    Score: 0.011
  64. Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Mol Carcinog. 2019 08; 58(8):1438-1449.
    View in: PubMed
    Score: 0.011
  65. RLIP: An existential requirement for breast carcinogenesis. Biochim Biophys Acta Rev Cancer. 2019 04; 1871(2):281-288.
    View in: PubMed
    Score: 0.011
  66. RLIP inhibition suppresses breast-to-lung metastasis. Cancer Lett. 2019 04 10; 447:24-32.
    View in: PubMed
    Score: 0.011
  67. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
    View in: PubMed
    Score: 0.011
  68. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Mol Carcinog. 2018 12; 57(12):1751-1762.
    View in: PubMed
    Score: 0.011
  69. Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. Cancer Lett. 2018 12 01; 438:144-153.
    View in: PubMed
    Score: 0.011
  70. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia. 1998 May; 12(5):637-44.
    View in: PubMed
    Score: 0.010
  71. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018 04 05; 173(2):470-484.e18.
    View in: PubMed
    Score: 0.010
  72. Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
    View in: PubMed
    Score: 0.010
  73. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57.
    View in: PubMed
    Score: 0.010
  74. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
    View in: PubMed
    Score: 0.009
  75. Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog. 1997; 8(4):343-58.
    View in: PubMed
    Score: 0.009
  76. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6.
    View in: PubMed
    Score: 0.009
  77. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
    View in: PubMed
    Score: 0.009
  78. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.009
  79. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
    View in: PubMed
    Score: 0.009
  80. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74.
    View in: PubMed
    Score: 0.009
  81. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.009
  82. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21; 11(6):1149-55.
    View in: PubMed
    Score: 0.009
  83. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 04; 290(36):21901-14.
    View in: PubMed
    Score: 0.008
  84. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15; 308(10):L1025-38.
    View in: PubMed
    Score: 0.008
  85. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
    View in: PubMed
    Score: 0.008
  86. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995 Mar 10; 270(10):5039-47.
    View in: PubMed
    Score: 0.008
  87. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.008
  88. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
    View in: PubMed
    Score: 0.008
  89. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem. 2014 Aug 29; 289(35):24043-58.
    View in: PubMed
    Score: 0.008
  90. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem. 2014 May 09; 289(19):13476-91.
    View in: PubMed
    Score: 0.008
  91. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
    View in: PubMed
    Score: 0.008
  92. Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. PLoS One. 2014; 9(3):e90059.
    View in: PubMed
    Score: 0.008
  93. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269.
    View in: PubMed
    Score: 0.007
  94. Altered membrane fluidity in rat hepatocytes during endotoxic shock. Mol Cell Biochem. 1993 Apr 21; 121(2):143-8.
    View in: PubMed
    Score: 0.007
  95. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets. 2013 May; 17(5):481-3.
    View in: PubMed
    Score: 0.007
  96. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
    View in: PubMed
    Score: 0.007
  97. Overexpression of the ยต-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
    View in: PubMed
    Score: 0.007
  98. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012 May; 26(5):2175-86.
    View in: PubMed
    Score: 0.007
  99. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J. 2011 Oct 01; 439(1):45-55.
    View in: PubMed
    Score: 0.007
  100. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50.
    View in: PubMed
    Score: 0.006
  101. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
    View in: PubMed
    Score: 0.006
  102. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67.
    View in: PubMed
    Score: 0.006
  103. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
    View in: PubMed
    Score: 0.006
  104. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
    View in: PubMed
    Score: 0.006
  105. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47.
    View in: PubMed
    Score: 0.006
  106. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 2009 Oct 02; 284(40):27524-32.
    View in: PubMed
    Score: 0.006
  107. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 2009 Jan 29; 28(4):518-33.
    View in: PubMed
    Score: 0.005
  108. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007 Oct 19; 282(42):30643-57.
    View in: PubMed
    Score: 0.005
  109. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.005
  110. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
    View in: PubMed
    Score: 0.005
  111. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
    View in: PubMed
    Score: 0.003
  112. A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem. 2002 Jun 07; 277(23):20887-94.
    View in: PubMed
    Score: 0.003
  113. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
    View in: PubMed
    Score: 0.003
  114. Flow cytometric determination of lipid peroxidation using fluoresceinated phosphoethanolamine. Methods Enzymol. 2002; 352:80-91.
    View in: PubMed
    Score: 0.003
  115. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9.
    View in: PubMed
    Score: 0.003
  116. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
    View in: PubMed
    Score: 0.003
  117. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
    View in: PubMed
    Score: 0.003
  118. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000 Mar 10; 275(10):6868-75.
    View in: PubMed
    Score: 0.003
  119. The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem. 2000 Jan 14; 275(2):1405-13.
    View in: PubMed
    Score: 0.003
  120. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
    View in: PubMed
    Score: 0.003
  121. Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. J Biol Chem. 1999 Nov 19; 274(47):33522-30.
    View in: PubMed
    Score: 0.003
  122. Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 03; 18(22):3343-53.
    View in: PubMed
    Score: 0.003
  123. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.
    View in: PubMed
    Score: 0.003
  124. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem. 1997 Dec 26; 272(52):33373-6.
    View in: PubMed
    Score: 0.003
  125. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 06; 15(19):2379-84.
    View in: PubMed
    Score: 0.002
  126. Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
    View in: PubMed
    Score: 0.002
  127. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85.
    View in: PubMed
    Score: 0.002
  128. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
    View in: PubMed
    Score: 0.002
  129. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
    View in: PubMed
    Score: 0.002
  130. Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of proteins to lysosomes is not irreversible. J Biol Chem. 1987 Jul 15; 262(20):9469-76.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.